Takeda braces for $2.5 billion charge after losing Amitiza antitrust case, plans appeal
Takeda Pharmaceutical has revised its financial outlook to include a potential $2.5 billion charge stemming from a recent antitrust lawsuit loss involving its laxative product Amitiza.
The US District Court in Massachusetts ruled against Takeda in May, finding that the company engaged in anti-competitive conduct related to Amitiza.
Takeda said it will appeal the decision and will reflect the estimated cost in its upcoming financial results.
The company did not disclose any additional settlements or changes to its product pipeline as a result of the ruling.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that